Eton Pharmaceuticals (ETON) announced the relaunch of Hemangeol. Hemangeol is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive. Hemangeol is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Starts Pilot Trial of ET-700 for Wilson Disease
- Eton Pharmaceuticals says first patient dosed in study of ET-700
- Eton Pharmaceuticals Announces New Chief Financial Officer Appointment
- Eton Pharmaceuticals appoints Judith Matthews as CFO
- Eton Pharmaceuticals Amends Credit Agreement, Eases Debt Terms